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The Ninth International Conference on the Hsp90 Chaperone Machine concluded in October 15 
2018, in Leysin, Switzerland. The program highlighted findings in various areas, including 16 
integrated insight into molecular mechanism of Hsp90, cochaperones, and clients’ structure and 17 
function.  18 
 3
Heat shock protein-90 (Hsp90) is a molecular chaperone critical for the folding, stability, and 19 
activity of client proteins 1. Hsp90 and its orthologs, including bacterial HtpG, mitochondrial 20 
TRAP1 and endoplasmic reticulum Grp94, exist as dimers, hydrolyze ATP, and cycle between 21 
distinct conformational states. Hsp90 preferentially binds proteins in near native states 22 
facilitating their remodeling for protein interactions and signaling. At the 9th International 23 
Conference on the Hsp90 Chaperone Machine approximately one-third of the attendees shared 24 
their data on Hsp90 structure and function through short talks (Figure 1). Here, we distill and 25 
summarize their findings. 26 
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Keynote Speaker 28 
To open the meeting, the keynote speaker Paola Picotti (Institute of Molecular Systems Biology, 29 
Zurich, Switzerland), presented a recently developed mass spectrometry method that enables 30 
analysis of protein structural changes on a proteome-wide scale in complex biological extracts. 31 
The approach can detect subtle alterations in secondary structure content, larger scale 32 
movements such as domain motions, and more pronounced transitions between folding states 33 
and aggregation events 2. Hsp90 chaperone machinery appears to be a good candidate for further 34 
analysis by this method. 35 
  36 
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Hsp90 Dynamics 37 
Carefully orchestrated conformational changes in Hsp90 are essential for its association with 38 
cochaperones and client proteins. David Agard (University of California, San Francisco, 39 
California, USA) provided the first atomic details for the Hsp90/Hsp70/HOP/glucocorticoid 40 
receptor (GR) client-loading complex. Unexpectedly, this heterocomplex contains two Hsp70s 41 
both in the ADP-bound state, one of which appears to be involved in the delivery of GR, while 42 
the other supports the cochaperone HOP. GR is largely intact, but like in the 43 
Hsp90:Cdc37:kinase complex 3, part of GR is unfolded, and threaded through the lumen of a 44 
partially closed Hsp90 dimer, where it interacts with a newly revealed client binding site on 45 
HOP. Together this suggests a common mechanism for Hsp90:client recognition.  46 
 Stefan Rüdiger (Utrecht University, the Netherlands) revealed that Hsp70 binds clients 47 
through highly hydrophobic regions that provide protection from misfolding. Subsequently, 48 
Hsp90 breaks this interaction and allows clients to self-fold into a native state. Cochaperones are 49 
not necessary for folding, but mainly work to slow this process. Thorsten Hugel (University of 50 
Freiburg, Germany) described cooperation between nucleotide and the two amino-terminal ATP-51 
binding pockets in an Hsp90 dimer using multicolor, single-molecule Förster resonance energy 52 
transfer (FRET). This novel technique adds an additional dimension that allowed for the 53 
discovery that ATP and Aha1 independently, but synergistically, promote closing of the 54 
nucleotide pocket, but work antagonistically to affect subsequent reopening 4. Katarzyna Tych 55 
from Matthias Rief’s Lab (Technische Universität München (TUM), Munich, Germany) 56 
described the dynamics of Hsp90 carboxy-terminal dimerization using single molecule optical 57 
tweezers. Interestingly, Hsp90 carboxy-terminal association has three dissociation rates that are 58 
controlled by the presence of ATP, which stabilizes this interaction by eliminating the weakest 59 
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interaction state.  60 
 Vinay Dahiya from Johannes Buchner’ group (TUM, Munich, Germany) described the 61 
chaperoning mechanism of Hsp70 and Hsp90 for “the guardian of the genome,” p53. Hsp70 62 
together with Hsp40 unfolds and inactivates p53. The Hsp70 NEF, Bag1 supports the release of 63 
p53 from Hsp70 and, in coordination with HOP, Hsp90 and ATP promotes the folding of p53 64 
and restores its DNA binding activity. Shannon Doyle from Sue Wickner’s Lab (NCI, NIH, 65 
Bethesda, Maryland, USA) showed that Hsp90 and Hsp70 directly interact in both Escherichia 66 
coli (E. coli) and yeast. The region of interaction on Hsp90 involves residues in the middle-67 
domain that also interact with several cochaperones and clients, while the interaction region on 68 
Hsp70 utilizes residues in the J-protein binding region of Hsp70 5. 69 
 70 
Hsp90 Phosphorylation and Regulation  71 
Hsp90 and its cochaperones are subject to post-translational modifications (PTMs) including 72 
phosphorylation. Ioannis Gelis (University of South Florida, Tampa, Florida, USA) 73 
demonstrated that during the chaperone cycle, Hsp90 phosphorylation occurs in a cochaperone 74 
regulated manner. This is exemplified by the Hsp90/Cdc37 heterocomplex, in which the 75 
phosphorylation of Cdc37 primes Hsp90 for phosphorylation of tyrosine 197, and controls 76 
disassembly of the client recruitment complex. Thus, Hsp90 cochaperone complexes are highly 77 
dynamic and highly regulated at many steps throughout the chaperone cycle 6. 78 
 Matthias Mayer (Universität Heidelberg, Germany) revisited previous works on PTMs of 79 
Hsp90 and how they fine tune Hsp90 function. His data based on yeast growth assays revealed 80 
that some phosphomimetic mutations of Hsp90 grow more efficiently than the wild-type Hsp90 81 
and more potently activate steroid hormone receptors, apart from GR. This supports the idea that 82 
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PTMs can tune Hsp90 specificity for chaperoning specific clients, even those that evolved from 83 
the same gene. 84 
 85 
Structure and function of Hsp90 Orthologs 86 
Dan Gewirth (Hauptman-Woodward Institute, Buffalo, New York, USA) presented data on the 87 
structure of the Pre-amino (Pre-N) domain of Grp94, the endoplasmic reticulum (ER) Hsp90, 88 
along with functional data showing its role in client protein maturation. The Pre-N domain 89 
regulates the ATPase activity of the chaperone and appears to functionally substitute for 90 
cochaperones of Hsp90, which are missing in the ER 7. 91 
 Olivier Genest (CNRS, Aix Marseille University, France) showed that Hsp90 is essential 92 
under heat stress in the aquatic bacterium Shewanella oneidensis 8. He found that TilS, a tRNA 93 
modifier, is a client of Hsp90 and that an interplay takes place between folding by Hsp90 and 94 
degradation by the protease HslUV to finely regulate the level of TilS. 95 
 96 
Modulation of Hsp90 by Cochaperones 97 
The chaperone function of Hsp90 is tightly regulated by cochaperones. Pierre Goloubinoff 98 
(University of Lausanne, Switzerland) proposed Hsp70 as the major cochaperone of Hsp90. 99 
Deletion studies in E. coli demonstrate that, unlike the deletion of Hsp70/Hsp40, which 100 
upregulated many chaperones and proteases while suppressing metabolic and respiratory 101 
enzymes, deletion of E. coli Hsp90 did not dramatically impact protein levels. This work also 102 
revealed that Hsp90 promotes the degradation of aggregation-prone clients of Hsp70/Hsp40 103 
through the HsIUV protease. 104 
 Kaushik Bhattacharya from Didier Picard’s group (University of Geneva, Geneva, 105 
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Switzerland) addressed the question of the importance of the HOP protein in eukaryotes 9. He 106 
found that the complex Hsp70-HOP-Hsp90 physically interacted with the proteasome. Although 107 
in the absence of HOP the proteasome activity is reduced, he showed that proteostasis is 108 
maintained by a “super-chaperone” complex minimally consisting of Hsp90, Hsp70, a J-protein 109 
and a nucleotide exchange factor, resembling the chaperone complex found in prokaryotes. 110 
Michael Reidy from Dan Masison’s group (NIDDK, NIH, Bethesda, Maryland, USA) reported 111 
that Sti1 (HOP) has two distinct functions for yeast Hsp90. The first function is to connect 112 
Hsp70 to Hsp90 by binding directly to both chaperones. The second function is to facilitate 113 
transfer of clients from Hsp70 to Hsp90 by priming Hsp90 for client loading. 114 
 The R2TP complex is a cochaperone of Hsp90 that includes RuvBL1 and RuvBL2, two 115 
AAA+ proteins involved in cancer progression 10. Walid Houry (University of Toronto, Toronto, 116 
Canada) developed a screen to find inhibitors of the RuvBL2 protein. He successfully identified 117 
a compound that inhibits RuvBL2. Chris Prodromou (University of Sussex, Brighton, UK) 118 
described the 3D structure of the yeast and human R2TP complex that was recently solved using 119 
X-ray crystallography and single-particle EM 11. These structures revealed the importance of the 120 
Hsp90 cochaperone complex as a hexamer-ring and that in yeast, binding of a single Tah1 121 
coupled to Pih1 could promote Rvb1p-Rvb2p ATPase activity. Philippe Meyer (Sorbonne 122 
Université, CNRS, Paris, France) presented the crystal structure of the human RPAP3 in 123 
complex with PIH1D1, important cochaperones in the R2TP complex that regulate Hsp90 124 
activity. This work revealed that the TPR2 domain in RPAP3 recruits Hsp90, which stimulates 125 
Hsp90 ATPase activity in synergy with Aha1. This stimulation activity is abolished if the amino-126 
terminus of RPAP3 is deleted. 127 
 Markus Zweckstetter (DZNE, Göttingen, Germany) described the 3D structure of Hsp90 128 
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in complex with misfolded transthyretin, which was similar to the binding previously described 129 
for tau 12. The impact of cochaperones on Hsp90 structure was also described using the example 130 
of FKBP51, which binds to all three domains of Hsp90 with varying affinities and results in 131 
reduced ATPase activity by stabilizing an open conformation of the amino-terminal domain. 132 
When bound to Hsp90, the catalytic site of FKBP51 remains accessible supporting the idea that 133 
Hsp90 likely acts as a scaffold to support the functional interaction of misfolded proteins with 134 
cochaperones. Mehdi Mollapour (SUNY Upstate Medical University, Syracuse, New York, 135 
USA) described the cooperative function of new cochaperones, Tsc1 and FNIP1/2. They work 136 
cooperatively to decelerate Hsp90 chaperone cycle and play a role in the chaperoning of both 137 
kinase and non-kinase clients 13. He also showed how phosphorylation, SUMOylation and 138 
ubiquitination of the cochaperone Protein Phosphatase-5 (PP5) regulate its activation, substrate 139 
binding and degradation in cancer. 140 
  141 
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Moonlighting Functions of Hsp90 142 
Several newly emerged moonlighting functions of Hsp90 at the nucleus and plasma membrane 143 
were revealed at this meeting. Brian Freeman (University of Illinois, Urbana, Illinois, USA), 144 
using an elegant single cell approach with a fluorescently marked DNA locus, demonstrated how 145 
Hsp90 is involved in chromosome motion within interphase cells. He showed that Hsp90 and 146 
p23 keep ARP-containing chromatin remodelers in a dynamic state allowing them to interact 147 
with target gene promoters, in turn directing actin polymer formation and chromosome motion. 148 
 Gergely Lukacs (McGill University, Montreal, Canada) showed that both eukaryotic 149 
(Hsc70 and Hsp90) and prokaryotic chaperone (DnaK) systems can reshape the conformational 150 
energetics of mutant CFTR channel final fold towards that of the wild-type at the single 151 
molecule level and in cells. This mechanism has implications in the regulation of metastable 152 
ABC-transporters and other membrane proteins. Dragana Vidovic, from Ineke Braakman’s group 153 
(Utrecht University, The Netherlands) reported that Hsp90 is required for a crucial step in 154 
folding of CFTR. More specifically Hsp90 is involved in folding of the CFTR nucleotide-155 
binding domain. Wild-type CFTR in the presence of compromised Hsp90 function is folded like 156 
the pathogenic mutant CFTR ∆F508. Michael Heider and Vanesa Fernandez-Saiz from Florian 157 
Bassermann’s Lab (TUM, Munich, Germany) described Cereblon (CRBN), the target of 158 
immunomodulatory drugs (IMiDs), as a novel regulator of the Hsp90-Aha1 axis that mediates 159 
maturation of transmembrane proteins such as CFTR. They also showed that Hsp90-CRBN 160 
interaction was abrogated upon IMiD-treatment, thus explaining CRBN-dependent IMiD 161 
induced destabilization of its transmembrane clients.  162 
 Shiran Dror from Anat Ben-Zvi’s group (Ben-Gurion University of the Negev, Beer 163 
Sheva, Israel) presented his work on the role of Hsp90 in myosin assembly in C. elegans. He 164 
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showed that knockout or overproduction of Hsp90 and some of its cochaperones resulted in loss 165 
of motility phenotypes due to myosin filament disorganization. Looking at chaperone 166 
localization patterns in the sarcomere, he proposed that Hsp90 machinery is important for 167 
regulating myosin translocation across the sarcomere allowing the formation of proper filaments 168 
of myosin. Yu-Chun Wang from Patrik Verstreken’s lab (VIB, Leuven, Belgium), showed a 169 
previously unexpected role of Hsp90 in membrane remodeling. In vitro and in vivo evidence 170 
indicated that Hsp90 interacts with membranes via an amphipathic helix, deforms the 171 
membranes and allows exosome release. This activity can be inhibited by Hsp90 inhibitors 14. 172 
 Christine Queitsch (University of Washington, Seattle, Washington, USA) described that 173 
the effects of Hsp90 on the evolutionary rate of protein kinases is comparable to effects of gene 174 
expression and protein interactions. She showed that a single mutation can render a non-client 175 
transcription factor Hsp90-dependent and that Hsp90-dependent de novo mutations do not 176 
account for most Hsp90-dependent phenotypes. 177 
 178 
Hsp90 in Maladies 179 
Hsp90 is involved in various maladies including cancer, neurodegenerative diseases, and 180 
pathogenic infections. Laura Blair (University of South Florida, Tampa, Florida, USA) 181 
demonstrated that Aha1 increases tau aggregation. In contrast, cyclophilin 40 (CyP40) disrupts 182 
tau fibrils reducing neurotoxicity in vivo 15. These findings provide strong rationale to develop 183 
therapeutics for tauopathies by targeting molecular chaperones. Aaron Voigt (RTWH Aachen 184 
University, Germany) demonstrated that mitochondrial Hsp90 TRAP1 is an important player in 185 
Parkinson’s disease (PD) and his data suggest that enhancing TRAP1 abundance or activity in 186 
neurons might be an avenue for future PD therapies. 187 
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 Oliver Krämer (Johannes Gutenberg University Mainz, Germany) presented his work on 188 
the involvement of Hsp90 and the histone deacetylase 6 (HDAC6) in acute myeloid leukemia 189 
(AML) cells. He showed that a combination of inhibitors directed towards HDAC6 and Hsp90 190 
triggered apoptosis of AML cells, providing new promising ways to treat AML. Ramona Schulz-191 
Heddergott (University Medical Center of Göttingen, Germany) described that stabilization of a 192 
cancer-relevant Hsp90 client p53-R248Q contributes to STAT3 hyper-activity. Vice versa, 193 
Hsp90 inhibition by 17AAG leads to degradation of the p53 mutant and thus, down-regulation of 194 
p-STAT3. This data suggests that the cancer-relevant Hsp90 client p53 mutants represent an 195 
actionable drug target for treatment with Hsp90 inhibitors.  196 
 Stephanie Diezmann (University of Bristol, Bristol, UK) described how Hsp90 and lack 197 
of the cochaperone Sti1 (HOP) enables phenotypic variation via loss-of-heterozygosity and 198 
aneuploidy in the ameiotic human fungal pathogen Candida albicans. She proposed the 199 
environmentally responsive chaperone Hsp90 as a novel mechanism for the creation of genetic 200 
diversity in C. albicans. Harriet Mok from Jason Mercer’s group (University College London, 201 
UK) highlighted the importance of Hsp90 in the life cycle of a poxvirus family member, vaccinia 202 
virus (VACV). Using microscopy and virus-specific assays, she showed that multiple isoforms 203 
of Hsp90 are required during late stages of vaccinia infection including successful genome 204 
release into the host cytoplasm and replication. 205 
 Joachim Clos (Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany) 206 
discussed the translatome changes in Leishmania donovani following Hsp90 inhibition. This 207 
protozoan parasite showed increased synthesis of proteins that are involved in oxidative stress 208 
protection, proteolysis, chromatin assembly, and chaperoning following Hsp90 inhibition. These 209 
results underscore the importance of Hsp90 in the control of the parasite’s life cycle. 210 
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 211 
Hsp90 in the Extracellular Environment 212 
The extracellular molecular chaperone Hsp90 (eHsp90, released or surface-bound) is responsible 213 
for chaperoning clients outside the cell. Wei Li (University of Southern California, Los Angeles, 214 
California, USA) provided a remarkable overview of the roles of extracellular Hsp90α in 215 
repairing injured tissues and in supporting tumorigenesis. During wound healing, secreted 216 
Hsp90α interacts with the extracellular domain of a receptor (LRP-1) that is stabilized by 217 
Hsp90β inside the cell. Hsp90α protects cells from hypoxia-triggered apoptosis and promotes 218 
cell motility to close the wound. Surprisingly, the activity of Hsp90α is independent of its 219 
ATPase activity and can be fulfilled by a short region of Hsp90α of only about 115 amino acids, 220 
called fragment-5 16. These properties of secreted Hsp90α have been taken advantage of by 221 
tumor cells to gain invasion and metastasis, representing an alternative target for anti-tumor 222 
therapeutics. Natasha Boel from Adrienne Edkins’ group (Rhodes University, Grahamstown, 223 
South Africa) investigated the role of Hsp90 in the dynamics of the fibronectin (FN) matrix. She 224 
showed that Hsp90 interacts with FN, and that inhibition of Hsp90 by novobiocin resulted in FN 225 
turnover via a LRP-1 receptor mediated response 17. 226 
 Patricija van Oosten-Hawle (University of Leeds, Leeds, UK) explained how a 227 
proteotoxic stress perceived in one tissue induces a response in other tissues leading to molecular 228 
chaperone activation via a pathway termed transcellular chaperone signaling (TCS). Using C. 229 
elegans, she showed that the zinc finger transcription factor PQM-1 is involved in mediating 230 
TCS 18. Importantly, she found that activating Hsp90 by TCS reduced the formation of toxic 231 
amyloid beta aggregates. 232 
 233 
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Small molecule inhibitors of Hsp90 234 
Hsp90 inhibitors that target the ATP binding pocket in the amino-terminal domain are currently 235 
evaluated in cancer patients. Brian Blagg (University of Notre Dame, Notre Dame, Indiana, 236 
USA) presented the design and development of two new scaffolds that selectively inhibit the 237 
Hsp90ß isoform 19. As a result of these studies, new isoform-dependent substrates were 238 
identified that can be selectively modulated via inhibition of Hsp90ß. In addition, it was 239 
observed that selective inhibition of Hsp90ß induces the degradation of HSF1, and thus, there is 240 
no induction of the heat shock response. Initial studies suggest that Hsp90ß-selective inhibition 241 
may overcome some of the obstacles encountered with the pan-Hsp90 inhibitors that have 242 
struggled in clinical trials. Timothy Haystead (Duke University, Durham, North Carolina, USA) 243 
presented data on tethered inhibitors of Hsp90 amino-terminal domain causing aggregation and 244 
reinternalization of the Hsp90 protein such that it accumulates intracellularly at high 245 
concentration. This observation led to development of a series of imaging agents for the 246 
detection of early metastatic disease as well as imaging of inflammatory responses to immune 247 
challenge. 248 
 249 
Understanding Hsp90 Function Through Artificial Intelligence 250 
William E. Balch (The Scripps Research Institute, La Jolla, California, USA) used a new 251 
Gaussian Process-based machine learning approach referred to as Variation Spatial Profiling 252 
(VSP) to show that diversity at the population level is sensitive to the buffering capacity of the 253 
proteostasis program. Based on Spatial CoVariance (SCV), genetic diversity contributing to 254 
misfolding disease found in the population can be displayed as high-dimensional phenotype 255 
landscapes. Application of these technologies reveal a map of the specific sequence-to-function-256 
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to-structure features of the client protein fold that are responsive to Hsp70-Hsp90 257 
chaperone/cochaperone management at molecular resolution 20. Gennady Verkhivker (Chapman 258 
University School of Pharmacy, Irvine, California, USA) described the step-wise fashion by 259 
which the Hsp90-Cdc37 heterocomplex recognizes client kinases through differential 260 
stabilization of kinase lobes. This work revealed that Hsp90 binds after Cdc37 and helps shed 261 
light on unique dynamics signatures of protein kinase clients/nonclients that dictate chaperone 262 
addiction and explain divergences in the regulatory mechanisms among structurally similar 263 
kinases. 264 
 265 
Recognition of Colleagues in the Hsp90 Field 266 
For the past sixteen years two leaders in the field, Didier Picard (University of Geneva, 267 
Switzerland) and Johannes Buchner (TUM, Munich, Germany), have organized the Hsp90 268 
conference biannually. At this 9th International Conference, they were recognized for their 269 
valuable contribution and outstanding service to the Hsp90 field and community. They were both 270 
acknowledged and thanked for their continuous support of students, post-doctoral fellows and 271 
new group leaders (Figure 1). 272 
  273 
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Figure legend 321 
 322 
Figure 1. Above- Participants of the Ninth International Conference on the Hsp90 Chaperone 323 
Machine. Below- Brian Freeman (far left) and Mehdi Mollapour (far right) presented recognition 324 
trophies to the meeting organizers, Johannes Buchner, Didier Picard (middle). Photos by 325 
Abhinav Joshi. 326 

